These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21465637)

  • 61. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Cohen IJ
    Pediatr Hematol Oncol; 1999; 16(2):87-8. PubMed ID: 10100266
    [No Abstract]   [Full Text] [Related]  

  • 63. Palonosetron is a Better Choice Compared With Ondansetron for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in a Resource-limited Pediatric Oncology Center: Results From a Randomized Control Trial.
    Chaudhary NK; John RR; Boddu D; Mahasampath G; Nesadeepam N; Mathew LG
    J Pediatr Hematol Oncol; 2019 May; 41(4):294-297. PubMed ID: 31026250
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
    Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
    Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tropisetron in the prevention of chemotherapy-induced acute emesis in pediatric patients.
    Uysal KM; Olgun N; Sarialioğlu F
    Turk J Pediatr; 1999; 41(2):207-18. PubMed ID: 10770660
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
    Rapoport BL
    Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome.
    Inoue M; Shoji M; Shindo N; Otsuka K; Miura M; Shibata H
    BMC Pharmacol Toxicol; 2015 Mar; 16():5. PubMed ID: 25889295
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chemotherapy-induced nausea and vomiting.
    Lohr L
    Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment.
    Bleiberg H; Van Belle S; Paridaens R; De Wasch G; Dirix LY; Tjean M
    Drugs; 1992; 43 Suppl 3():27-32. PubMed ID: 1380430
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Chemotherapy-induced nausea and vomiting : Current recommendations for prophylaxis].
    Storz E; Gschwend JE; Retz M
    Urologe A; 2018 May; 57(5):532-542. PubMed ID: 29589051
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Nathan PC
    Paediatr Drugs; 2003; 5(9):597-613. PubMed ID: 12956617
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
    Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
    Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Integration of a nausea and vomiting assessment tool into antineoplastic management of pediatric oncology patients.
    McKinnon K; Jupp J
    J Oncol Pharm Pract; 2020 Sep; 26(6):1353-1360. PubMed ID: 31865847
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Prevention and control of chemotherapy-induced nausea and vomiting].
    Gómez-Raposo C; Feliú-Batlle J; González-Baróna M
    Med Clin (Barc); 2006 Feb; 126(4):143-51. PubMed ID: 16472500
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV).
    Herrstedt J; Aapro MS; Roila F; Kataja VV;
    Ann Oncol; 2005; 16 Suppl 1():i77-9. PubMed ID: 15888767
    [No Abstract]   [Full Text] [Related]  

  • 79. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
    Aapro MS
    Ariz Med; 1981 Nov; 38(11):843-5. PubMed ID: 6274276
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.